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ABSTRACT 
background: Vascular access problems are one of the main concerns in the diabetic 
end-stage kidney disease (ESKD) population. However, the optimal strategy for the 
establishement of vascular access in this population remains to be solved. We 
performed a systematic review in order to clarify the most advisable approach of 
vascular access planning in diabetic patients with ESKD.  
Methods: MEDLINE, EMBASE and CENTRAL databases were searched for English-
language articles without time restriction through focused, high sensitive search 
strategies. We included all studies providing outcome data on diabetics starting chronic 
haemodialysis treatment on the basis of the type of priamry placed vascular access.  
Results: A total of 13 studies comprising over 2800 participants with diabetes were 
reviewed in detail and included in the review. We found that diabetic patients using a 
dialysis catheter apparently experience a higher risk of death and infection compared 
with patients who successfully achieved and maintained an arteriovenous fistula as 
dialysis access. The comparison between the use of a graft or an autogenous fistula as 
dialysis access generated conflicting results. Primary patency rates appeared to be lower 
in diabetics versus non-diabetics.  Our study suggests that diabetic ESKD patients with 
dialysis catheters incur a higher risk of death in comparison to those who achieve an 
arteriovenous access.  
Conclusion: Our study suggests that diabetic ESKD patients with dialysis catheters 
incur a higher risk of death in comparison to those who achieve an arteriovenous access. 
It is however unclear whether this is caused by residual selection bias or by a true 
advantage of native vascular access. 
 
INTRODUCTION 
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The incidence and prevalence end-stage kidney disease (ESKD) has been growing over 
the last decade by 4-8% per annum worldwide, with diabetes mellitus (DM) as one of 
the leading causes (1). In parallel, the number of surgical and interventional procedures 
required to establish and maintain the arteriovenous vascular access for haemodialysis 
(HD) keeps rising every year (2). Despite many efforts, many patients are still dialyzed 
on a permanent tunneled catheter (PTC), although there is considerable geographic 
variation. DOPPS I data indicate that in Europe, HD patients were 3-fold more likely to 
have an autogenous arteriovenous fistula (AVF) as compared to North America. 
However, between DOPPS I and III, AVF use increased to 47% in the United States and 
decreased slightly from 80% to 74% in Europe (3). Actually, the proportion of prevalent 
HD patients with permanent catheters in Europe has been estimated to be as high as 
25% (4). The increase of comorbidities such as DM (from 18% to 33%), and vascular 
disease (from 22% to 34%) in HD patients between DOPPS I and III probably led to 
higher proportions of patients at risk for unsuccessful AVF creation.  
In an effort to improve vascular access outcomes, the National Kidney Foundation and 
the European Renal Association/European Dialysis and Transplant Association 
published guidelines for vascular access (5, 6). Based on these recommendations, a 
special project was launched in the United States, known as the Fistula First 
Breakthrough Initiative (7). The purpose of this initiative was to increase the likelihood 
that every patient would receive an autogenous vascular access. The Work Group 
however recognized after a while that in some cases, the “fistula first at all costs” 
approach leads to non-maturation and access failure despite repetitive interventions in 
certain subgroups, including diabetics, elderly and those with peripheral vascular 
disease (3, 4). Therefore, it is uncertain whether attempting to create a fistula first in 
these high risk patients is the most cost-effective or optimal solution for each individual. 
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With this background in mind, we performed a systematic review of the 
available evidence to clarify what is the most advisable strategy of vascular access 
planning in diabetic ESKD patients (with respect to type -catheter, autogenous fistula or 
graft- and position) in terms of impact on patient- and technique-centered outcomes.  
 
METHODS 
Data source and search strategy 
MEDLINE, EMBASE and CENTRAL databases were searched for English-language 
articles without time restriction through focused, high sensitive search strategies 
(Supplementary Table 1). References from relevant studies and reviews published on 
the same topic were screened for supplementary articles.  
 
Study selection 
We included any study providing outcome data on diabetics on chronic haemodialysis 
treatment on the basis of the type of vascular access primarily attempted. Studies were 
considered without restrictions of duration of follow-up. Diabetes (type I or II) was 
considered when it was either a cause of end-stage renal disease or a superimposed 
condition. We considered any possible type of vascular access, including: tunnelled 
catheters placed in any position (Jugular vein, Femoral vein, Subclavian vein), grafts 
placed in any position (Radial artery, Brachial artery) or autogenous fistulas placed in 
any position (Radial artery, Brachial artery). Outcomes of interest were: vascular access 
patency, vascular access infections, all cause- and cardiovascular-mortality. Studies 
were excluded if: 1) not dealing with diabetics; 2) not providing the above mentioned 
outcome data in relationship to the type of first placed vascular access; 3) dealing with 
vascular accesses not related to haemodialysis. Case reports, reviews, editorials, letters 
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and studies performed on children (age<18) or animals were excluded as well, although 
screened as potential sources of additional references. Selection of relevant studies were 
independently performed by two Authors (DB and LC). Discrepancies were solved 
collegially by discussion amongst DB and LC.  
 
Quality assessment 
We used the Newcastle-Ottawa Scale to assess the study quality for observational 
studies. This scale considers a quality score calculated on the basis of three major items: 
Study participants (0 to 4 points), adjustment for confounding (0 to 2 points) or 
ascertainment of the exposure or outcome of interest (0 to 3 points) with a maximum 
score of 9 points which represents the highest methodological quality.  
 
Data extraction and analysis 
Data extraction and analysis were performed by two reviewers independently (DB and 
LC). In studies considering mixed populations, the subgroup of patients with 
documented diabetes was selectively described only if corresponding data were 
available.  
 
RESULTS 
Search results 
The flow diagram of the selection process is depicted in Figure 1. Two hundred and 
sixty-two potentially relevant references were initially found. A total of 213 citations 
were excluded after title/abstract skimming because they were clearly not pertinent for 
the topic of our review or because of search overlap. Amongst the 49 studies selected 
for full text examination, 36 studies were excluded because of the following: dealing 
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with an inappropriate population/problem (n=16), dealing with an inappropriate 
intervention (n=4) or not including a proper comparator (n=13), no outcome data 
available (n=3). A total of 13 studies were therefore reviewed in detail and included in 
the review. Main characteristics of these studies are summarized in Table 1.  
 
Study characteristics 
Amongst the thirteen studies reviewed, two were prospective cohort studies (8, 9), ten 
were retrospective cohort studies (10-19) and one was a case-control study (20). The 
number of patients ranged from 127 (15) to 5198 (12). Diabetes was present in 22 (8) to 
55% (20) of the study populations. Follow up duration ranged from 24 (11) to 80 (12) 
months. The overall study quality was low to moderate.  
Ravani et al. (8) analyzed a cohort of 197 incident HD patients (22% DM) who 
underwent distal and proximal AVF creation by nephrologists in a single-centre. At the 
start of HD therapy, 117 patients (59.7%) had a dialysis catheter and the remaining 
patients had an AVF. Saxena et al. (9) analyzed the vascular access-related sepsis and 
mortality among 218 HD patients (29% DM) with different types of vascular access 
(AVF, AVG, temporary and permanent dialysis catheters). In the study of Chan et al. 
(10), a cohort of 764 incident HD patients with >65 years old (43% DM) who 
underwent AVF and AVG creation were studied. Patients with dialysis catheters were 
excluded. David et al. (11), analyzed the vascular access patency in a cohort of 274 
chronic kidney disease patients (26% DM) referring to AVF creation at several 
locations (distal, middle-arm and proximal AVF). Dhingra et al. (12) analyzed the all-
cause, cardiovascular and infection-related mortality among a cohort of 5189 HD 
patients (31% DM) with AVF, AVG and dialysis catheters. Diehm et al. (13) analyzed 
the vascular access patency on a cohort of 244 HD patients (25% DM) with different 
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types of vascular access (AVF, AVG and dialysis catheters). In the study of Field et al. 
(14), a cohort of 289 incident HD patients (36% DM) who underwent distal and 
proximal AVF creation was studied. Hammes et al. (15) analyzed a cohort of 127 
incident HD patients (41% DM) who underwent AVF angiography aiming to determine 
the time to the development of clinically significant stenosis among patients with and 
without cephalic arch lesions. Konner et al. (16) analyzed the vascular access patency 
and patient survival in a cohort of 247 chronic kidney disease patients (23% DM) who 
underwent distal or proximal AVF creation in a single-center. In a later study of Konner 
et al. (17), the authors analyzed the primary and cumulative patency rates in a cohort of 
748 chronic kidney disease patients (24% DM) who underwent either distal, proximal 
perforating or non-perforating vein AVF creation in a single center. Murphy et al. (18), 
analyzed a cohort of 293 chronic kidney disease patients (23% DM) who underwent 
proximal AVF creation in a single center, comparing <65 and >65 year-old, and male 
versus female patients. Leapman et al. (19) analyzed a cohort of 150 chronic kidney 
disease patients (34% DM) who underwent wrist AVF creation, aiming to determine the 
cumulative patency of the vascular access. In the study of Yeager et al. (20), a 
population of 222 HD patients (54% DM) was analyzed. Patient survival was 
determined among those with finger gangrene and those without it.  
 
Study Outcomes 
Mortality  
Dhingra et al. (13) reported a higher all-cause, infection-related and cardiovascular-
related mortality among patients with a dialysis catheter, in comparison to those with an 
AVF (RR=1.54, p<0.002). Also, all-cause and infection-related mortality was 
significantly higher among those with an AVG versus AVF (RR=1.41, p<0.003). On the 
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other hand, in the study of Chan et al. (10), mortality was not significantly higher in 
patients with an AVG compared to those with an AVF (RR=1.34, p=0.123). Finally, 
Konner (16) described a higher mortality rate among DM patients with an AVF versus 
non-DM patients (70% versus 40% at 60 months follow-up, respectively). 
 
Vascular access patency 
Ravani et al. (8), Diehm et al. (13) and Konner (16) reported lower patency rates of 
AVF among DM versus non-DM patients (HR 2.38, p=0.04; OR 0.4, 95% CI 0.2-0.7, 
respectively). On the other hand, Murphy et al. (18) and Field et al. (14) reported 
similar AVF patency rates between DM and non-DM patients (approximately 40% and 
30%, respectively; no effect measure reported). Within the DM group, both Ravani et 
al. (8) and Konner (16) reported similar secondary patency rates among those with 
distal versus proximal AVF and Murphy et al. (18) reported similar cumulative patency 
rates between young and older patients. On the other hand, Field et al. (14) reported a 
higher patency rate for DM patients with a proximal versus distal AVF and Murphy et 
al. (18) reported a higher patency rate in male versus female DM patients. In these 
studies, comparisons within the DM population were entirely descriptive. In another 
study, Konner et al. (17), reported a lower primary patency rate in patients with non-
perforating proximal AVF versus perforating proximal AVF and distal AVF 
(approximately 50%, 80% and >80%, respectively); the cumulative patency rates 
among the three study groups was similar (approximately 90%, 80% and 80%, 
respectively) and the thrombosis rate was lower among those with a proximal 
perforating AVF (6.3, 3.0 and 0.8 per 100 patients-at risk; no effect measure reported). 
In the study of Chan et al. (10), the authors reported similar vascular access patency 
rates between patients with an AVF and an AVG (60 versus 50%, OR=1.49, p=0.244). 
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David et al. (11) described similar patency rates between distal, middle-arm and 
proximal AVF (57%, 55% and 30%, respectively). Hammes et al. (15) reported that the 
presence of cephalic arch stenosis in DM patients with an AVF was not a risk factor for 
the development of a subsequent stenosis. Finally, Yeager et al. (20), reported that DM 
and premature atherosclerotic disease were independent risk factors for finger gangrene. 
 
Vascular access-related infections 
The study of Saxena et al. (9), showed that vascular access-related sepsis was 
significantly lower among patients with an AVF (8.3%) in comparison with those with 
an AVG (33.3%) or a permanent dialysis catheter (27.3%) (AVG vs. AVF, RR=4.02, 
p<0.0006; permanent catheter vs. AVF, RR=3.29, p<0.03). Patients with temporary 
femoral catheters presented the highest sepsis-related mortality (100%, RR=5.78, 
95%CI 1.55-21.54). Dhingra et al. (13), reported a higher vascular access-related 
infection associated mortality among DM patients with permanent catheters and AVGs, 
in comparison with those with AVFs (RR=2.30, p=0.06; RR=2.47, p=0.02; 
respectively). 
 
 
DISCUSSION 
In our systematic review, including 13 studies comprising over 2800 participants with 
DM, we found that DM patients using a dialysis catheter apparently experience a higher 
risk of death and infection compared with patients who successfully achieved and 
maintained an AVF as HD access. Primary patency rates appeared to be lower in 
diabetics versus non-diabetics.  The comparison between the use of an AVG or an AVF 
as HD access generated conflicting results.  
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The preference of AVF over all other forms of access arises from their 
functional advantages because of a lower rate of complications. Autogenous fistulae 
have lower rates of infections than catheters and AVGs, and the lowest rate of 
thrombosis, providing longer survival of the access (5, 6). Perl et al. (21) reported that 
patients starting HD using a central venous catheter had a higher risk of death in the 
first year compared to those who started HD with an AVF or AVG. Ravani et al. (22) 
performed a systematic review aiming to quantify the associations between vascular 
access type and mortality, infection, and cardiovascular events. The authors showed that 
persons using central venous catheters for HD experience a much higher risk of death, 
infection, cardiovascular events, and hospitalization compared with persons who 
achieve an AVF or an AVG as HD access. However, AVG use was also associated with 
increased risk of death, infection, and hospitalization, compared to the use of an AVF. 
Nevertheless, since most of the data on this field was obtained from observational 
studies, there is always the reservation that adjustment for baseline comorbidity cannot 
be complete. As a consequence, the presence of a functioning AVF is probably a marker 
of a patient’s health and adherence, and so all or even most of the superior outcome may 
not be related to the AVF itself but rather to selection bias (23). On the contrary, 
catheter use is associated with acute illness and late presentation for dialysis, factors that 
are associated with high mortality and that may be difficult to adjust for. Dhingra et al. 
(13) reported a lower survival among those patients using an AVG and Chan et al. (10) 
reported similar outcomes between ESRD patients achieving an AVF or an AVG. 
However, the study populations on these two studies were quite different - Dhingra et 
al. (13) included HD patients > 15 years old and Chan et al. (10) included only HD 
patients > 65 years old. Although overall ESKD diabetic patients probably do better 
with an AVF, in comparison with a dialysis catheter or an AVG, diabetic patients aged 
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65 years and older probably may experience similar outcomes either with an AVF or 
graft. 
Our review suggests that diabetic patients have a decreased odds for vascular 
access long-term survival, often resulting in repetitive interventions. There is no 
sufficient data to allow meaningful comparison of different techniques and locations on 
the arm (wrist/forearm/elbow), and existing data are conflictive. It is likely that this is 
just a reflection of different case-mix, bias by indication and experience of involved 
surgeons.  It seems obvious in the light of good surgical practice that when planning 
permanent access placement, one should always consider the most distal site possible 
because it preserves more proximal vessels and it has fewer complications (5).  
However, the major disadvantage of distal AVF is the relatively high primary failure 
rate. In view of the more limited life expectancy, a primary choice for more proximal 
places can be discussed, especially in the elderly and in those with additional 
comorbidities. In this regard, vascular mapping in preparation for the creation of a 
vascular access should be performed in all patients in order to maximize the chance of 
AVF placement success (5, 6).   
Our review has some strengths and limitations that deserve mentioning. 
Strengths include that we performed a systematic search of medical databases, and that 
data extraction and analysis were made by two independent reviewers according to 
current methodological standards. However, although comprehensive search strategies 
were implemented, publication bias cannot be excluded. In order to maximize the 
number of included studies we decided to adopt broad criteria, considering any paper 
including at least a subpopulation of HD patients with acknowledged DM and outcome 
data available according to the first type of vascular access placed. Yet, in most studies 
diabetics often represented only a minor subpopulation of the whole study cohort. This 
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may therefore hamper the generalizability of findings to the whole diabetic HD 
population. There was a high heterogeneity among studies with respect to the study 
design, number of subjects enrolled, severity and vintage of diabetes, presence of co-
morbidities and, above all, age, which prevented us to perform data pooling. 
Furthermore, all the studies had an observational design (mostly retrospective) and we 
were unable to find even a single randomized trial providing useful data for our review 
purpose. Also of note, data on the rates of vascular access patency were often only 
descriptive. This, again, makes it highly challenging to draw even a preliminary 
conclusion on what is the optimal vascular access for HD to be universally 
recommended in diabetics.  
In conclusion, although it is widely recognized that an AVF appears to be the 
access of choice for younger and healthier HD diabetic patients, the everlasting question 
concerning older, sicker patients with risk factors for AVF failure and associated 
complications still remains unresolved. Patients should be well informed on the 
available evidence on vascular access. A strategy whereby reasonable effort is done to 
create an autogenous vascular access in those with good prognosis, both with regard to 
primary patency as to life expectancy, seems to be a defendable approach based on the 
available evidence. Much more clinical investigations in this important field are 
urgently needed, in view of the importance for this increasing patient group. 
 
 
ACKNOWLEDGMENTS 
This systematic review was performed as part of guideline production process by 
European Renal Best Practice (ERBP) on management of diabetics with advanced 
Chronic Kidney Disease (CKD). The Guideline Development Group of that project 
13 
 
consists of Wim Van Biesen (Chair), Henk Bilo, Davide Bolignano, Louis Coentrao, 
Cecile Couchoud, Adrian Covic, Christiane Drechsler, Johan De Sutter, David 
Goldsmith, Luigi Gnudi, Kitty Jager, James Heaf, Olle Heimburger, Hakan Nacak, 
Maria Soler, Charlie Tomson, Liesbeth Van Huffel, Steven Van Laecke, Laurent 
Weekers, Andrzej Wiecek,  
 
Declaration of Interest 
None of the Authors reports a conflict of interest with regard to issues dealt with in this 
systematic review. The declarations of interest of interest of the different authors can be 
found online at www.european-renal-best-practice.org 
14 
 
REFERENCES 
1. Ethier J, Mendelssohn D, Elder S, Hasegawa T, Akizawa T, Akiba T, et al. 
Vascular access use and outcomes: an international perspective from the dialysis 
outcomes and practice patterns study. Nephrol Dial Transplant 2008;23: 3219-
3226. 
2. USRDS. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage 
Renal Disease in the United States, National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2010. 
3. Young E, Dykstra D, Goodkin D, Mapes D, Wolfe R, Held P. Hemodialysis 
vascular access preferences and outcomes in the Dialysis Outcomes and Practice 
Patterns Study (DOPPS). Kidney Int 2002; 61: 2266-2271. 
4. Ravani P, Spergel L, Asif A, Roy-Chaudhury P, Besarab A. Clinical 
epidemiology of arteriovenous fistula in 2007. J Nephrol 2007; 20: 141-149. 
5. NKF-KDOQI. Clinical practice guidelines for vascular access. Am J Kidney Dis 
2006; 48 (Suppl 1): S248–S272. 
6. Tordoir J, Canaud B, Haage P,  Konner K, Basci A, Fouque D, et al. EBPG on 
vascular access. Nephrol Dial Transpl 2007;22(Suppl 2):ii88-ii117. 
7. http://www.FistulaFirst.org/. 
8. Ravani P, Marcelli D, Malberti F. Vascular Access Surgery Managed by Renal 
Physicians: The Choice of Native Arteriovenous Fistulas for Hemodialysis  
References. American Journal of Kidney Diseases 2002;40 (6):1264-1276. 
15 
 
9. Saxena AK, Panhotra BR, Naguib M, Sundaram DS, Ventakeshappa CK, 
Uzzaman W, et al. Outcome of dialysis access-related septicemia among 
diabetics following optimized AV-fistula placement. Kidney & Blood Pressure 
Research; 2002; 25:109-114. 
10. Chan MR, Sanchez RJ, Young HN, Yevzlin AS. Vascular Access Outcomes in 
the Elderly Hemodialysis Population: A USRDS Study. Seminars in Dialysis 
2007;20(6):606–610. 
11. David P, Navino C, Capurro F, Mauri Ade, Chiarinotti D, Ruva CE, et al. 
Láccesso vascolare per dialisi su vasi nativi nel paziente diabético: esperienza di 
un singolo centro. G Ital Nefrol 2010; 27 (5): 522-526. 
12. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey S, Port F. Type of 
vascular access and mortality in U.S. hemodialysis patients. Kidney 
International 2001, 60: 1443–1451. 
13. Diehm N, van den Berg1 JC, Schnyder V, Bühler J, Willenberg T, Widmer M, et 
al. Determinants of haemodialysis access survival. VASA 2010; 39: 133–139. 
14. Field M, Bailey G, Jaipersad A, Morgan rH, Pherwani AD. Primary patency 
rates in AV fistulae and the effect of patient variables. The Journal of Vascular 
Access 2008;9:45-50. 
15. Hammes M, Funaki B, Coe FL.  Cephalic arch stenosis in patients with fistula 
access for hemodialysis: Relationship to diabetes and thrombosis. Hemodialysis 
International 2008; 12:85–89. 
16 
 
16. Konner K. Primary vascular access in diabetic patients: an audit. NDT 
2000;15:1317-1325. 
17. Konner K, Hubert-Shearon E, Roys EC, Roys E, Porto F. Tailoring the initial 
vascular access for dialysis patients. Kidney International 2002;62:329–338. 
18. Murphy GJ, Nicholson ML. Autogeneous Elbow Fistulas: the Effect of Diabetes 
mellitus on Maturation, Patency, and Complication Rates. Eur J Vasc Endovasc 
Surg 2002;23: 452-457. 
19. Leapman SB, Boyle M, Pescovitz MD. The arteriovenous fistula for 
hemodialysis access. Gold standard or archaic relic? Am Surg 1996;62:652-656. 
Yeager RA, Moneta GL, Edwards JM, Landry GJ, Taylor LM, McConnell DB, 
et al. Relationship of hemodialysis access to finger gangrene in patients with 
end-stage renal disease. J Vasc Surg 2002;36:245-249. 
20. Perl J, Wald R, McFarlane P, Bargman JM, Vonesh E, Na Y, Jassal SV, et al. 
Hemodialysis Vascular Access Modifies the Association between Dialysis 
Modality and Survival. J Am Soc Nephrol 2011;22: 1113-1121.  
Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, Pannu NI, et 
al. Associations between Hemodialysis Access Type and Clinical Outcomes: A 
Systematic Review. J Am Soc Nephrol 2013; 24(3):465-473. 
 
 
 
17 
 
 
21.  Lee HW, Allon M. When Should a Patient Receive an Arteriovenous Graft 
Rather Than a Fistula? Semin Dial 2013;26:6-10. 
Table I. Summary of studies included in this review 
Author Year Study type Population Follow up Vascular access Outcome(s) Results 
Chan  
et al. 
2007 Retrospective 
multicentre 
cohort study 
Prevalent 
haemodialysis 
patients 
25 months AVF  
AVG 
Patient survival 
AVF vs. AVG 
 
 
Survival of the technique 
AVF vs. AVG 
 
 
60% vs. 50% (~) 
OR=1.34 (p=0.123) 
 
60% vs. 50% (~) 
OR=1.49 (p=0.244) 
 
David et 
al. 
 
2010 Retrospective 
single-centre 
cohort study 
Incident 
haemodialysis 
patients 
80 months Distal AVF  
Middle-arm AVF 
Proximal AVF 
Survival of the technique 
      Distal AVF  
      Middle-arm AVF 
      Proximal AVF 
 
57% (*) 
55% 
30% 
 
Dhingra et 
al.  
2001 Retrospective 
multicentre 
cohort study 
Haemodialysis 
patients 
2 years AVF 
AVG 
CVC 
Patient survival 
      CVC vs. AVF 
 
 
      AVG vs. AVF 
 
Vascular access-related infection 
associated mortality: 
       CVC vs. AVF 
       AVG vs. AVF 
 
 
60% vs. 70% (~) 
RR=1.54 (p<0.002) 
 
65% vs. 70% (~) 
RR=1.41 (p<0.003) 
 
 
RR=2.30 (p=0.06) 
RR=2.47 (p=0.02) 
Diehm 
et al. 
2010 Retrospective 
single-centre 
cohort study 
Chronic kidney 
disease patients 
2 years AVF 
AVG 
CVC 
Survival of the technique 
DM vs. non-DM 
        
        
 
 
 
Primary patency rate 
OR 0.6 (95%CI 0.3-1.0) 
 
Secondary patency rate 
OR 0.4 (95%CI 0.2-0.7) 
Field  
et al. 
2008 Retrospective 
single-centre 
cohort study 
Incident 
haemodialysis 
patients 
 Distal AVF 
Proximal AVF 
Survival of the technique 
DM vs. non-DM 
 
DM 
 
34% vs. 26% (p=0.11) 
 
Better survival of proximal 
Table
vs. distal AVFs (*) 
 
Hammes 
et al. 
2008 Retrospective 
single-centre 
cohort study 
Incident 
haemodialysis 
patients who 
underwent fistulae 
angiography 
78 months AVF Survival of the technique 
 
Similar rate of subsequent 
stenosis between patients 
with/without cephalic arch 
stenosis (*) 
 
Konner  
et al. 
2000 Retrospective 
single-centre 
cohort study 
Incident 
haemodialysis 
patients 
72 months Distal AVF 
Proximal AVF 
Patient survival 
 
 
Survival of the technique 
 
Lower survival rates in 
diabetic patients(*) 
 
Similar primary patency 
rates between groups (*) 
 
Leapman 
et al.  
1996 Retrospective 
single-centre 
cohort study 
Incident 
haemodialysis 
patients 
5 years AVF Survival of the technique 
DM vs. non-DM 
    
 
1 year (*) 
42% vs. 63% 
 
5 year (*) 
18% vs. 36% 
 
Murphy et 
al.  
2002 Retrospective  
single-centre 
cohort study 
Incident 
haemodialysis 
patients 
1 year Proximal AVF Survival of the technique 
DM vs. non-DM 
 
DM  <65 vs. >65yo 
DM male vs. female 
 
39% vs. 40% (p=N.S.) 
 
59% vs. 59%  (*) 
69% vs. 47%  
 
Ravani  2002 Prospective  
single-centre 
cohort study 
Incident 
haemodialysis 
patients 
3 years Distal AVF 
Proximal AVF 
Survival of the technique 
DM vs. non-DM 
       
       
 
 
 
DM 
 
Primary patency 
HR=1.85, p=0.01 
 
Cumulative patency 
HR=2.38, p=0.04 
 
Similar results between 
distal and proximal AVF 
(*) 
 
  
Saxena 2002 Prospective 
single-centre 
cohort study 
Haemodialysis 
patients 
4 years AVF 
AVG 
Permanent CVC 
Subclavian CVC 
Femoral CVC 
Vascular access-related infection 
associated mortality 
     AVF (Ref.) 
    AVG  
    permanent CVC 
    subclavian CVC 
   femoral CVC 
 
Vascular access-related infections 
    AVF (Ref.) 
    AVG  
    permanent CVC 
   subclavian CVC 
   femoral CVC 
 
 
15% 
42% (p<0.0006) 
33% (p<0.03) 
37.5% (p<0.001) 
100% (p<0.0005) 
 
 
0.04/patient-year 
1.07/patient.year 
1.15/1000 catheter-days 
1.3/1000 catheter-days 
1.5/1000 catheter-days 
Yeager 2002 Retrospective 
single-centre 
case-control 
study 
Haemodialysis 
patients with finger 
gangrene 
3 years AVF 
 
Patient survival 
(finger gangrene vs. no-finger 
gangrene) 
 
 
52% vs. 49% (*) 
Konner 2002 Retrospective  
single-centre 
cohort study 
Chronic kidney 
disease patients 
 Distal AVF 
Proximal 
perforating AVF 
Proximal non-
perforating AVF 
Primary patency rate 
     Distal AVF 
     Proximal perforating   AVF 
     Proximal non-perforating AVF 
 
Cumulative patency rate: 
     Distal AVF 
     Proximal perforating   AVF 
     Proximal non-perforating AVF 
 
Thrombosis rate: 
     Distal AVF 
     Proximal perforating   AVF 
     Proximal non-perforating AVF 
 
80% (*) 
>80% 
50% 
 
 
90% 
80% 
50% 
 
 
6.3 
0.8 
3.0 
AVF: arteriovenous fistula; AVG, arteriovenous graft; DM, Diabetes Mellitus 
* No effect measure reported 
  
Figure 1
Click here to download high resolution image
Supplementary Table I. Focused search strategy in CENTRAL and MEDLINE-
EMBASE databases 
CENTRAL 
 fistula*:ti,ab,kw 
  (shunt or shunts):ti,ab,kw 
  (graft or grafts*):ti,ab,kw 
  “blood vessel prosthesis”:kw 
 catheter*:ti,ab,kw 
 central next line*:ti,ab,kw 
 (AVF or AVG or CVC):ti,ab,kw 
 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7) 
 dialysis:ti,ab,kw 
 (hemodialysis or haemodialysis):ti,ab,kw 
 (hemodiafiltration or haemodiafiltration):ti,ab,kw 
 (hemofiltration or haemofiltration):ti,ab,kw 
  “chronic kidney”:ti,ab,kw 
  “chronic renal”:ti,ab,kw 
  “kidney failure”:ti,ab,kw 
  (“end-stage kidney” or “end stage kidney” or “end-stage renal” or “end stage renal” or 
“endstage kidney” or “endstage renal”):ti,ab,kw 
  (CKF or CKD or CRF or CRD):ti,ab,kw 
 (ESKF or ESKD or ESRF or ESRD):ti,ab,kw 
 (“pre-dialysis” or predialysis):ti,ab,kw 
 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19) 
 MeSH descriptor Diabetes Mellitus, this term only  
 MeSH descriptor Diabetes Mellitus, Type 1 explode all trees  
 MeSH descriptor Diabetes Mellitus, Type 2 explode all trees  
 MeSH descriptor Diabetic Nephropathies explode all trees  
 diabet*:ti,ab,kw  
 (niddm or iddm):ab,ti,kw  
 (#21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27) 
 (#8 AND #20 AND #28) 
 
MEDLINE 
 randomized controlled trial.pt. 
 controlled clinical trial.pt. 
 randomi?ed.ab,ti. 
 placebo$.ab,ti. 
 drug therapy.fs. 
 randomly.ab,ti. 
 trial$.ab,ti. 
 group$.ab,ti. 
 or/1-8 
 Meta-analysis.pt. 
 exp Technology Assessment, Biomedical/ 
 exp Meta-analysis/ 
 exp Meta-analysis as topic/ 
 (health technology adj6 assessment$).tw,ot. 
 hta.tw,ot. 
 (meta analy$ or metaanaly$ or meta?analy$).tw,ot. 
 exp Cohort studies/ 
 Incidence.tw. 
 exp mortality/ 
 exp follow-up studies/ 
Supplementary material
Click here to download Supplementary material: Supplementary Table I.doc 
 mo.fs. 
 prognos$.tw. 
 predict$.tw. 
 course.tw. 
 exp survival analysis/ 
 (comment or editorial or historical-article).pt. 
 Arteriovenous Fistula/ 
 Arteriovenous Shunt, Surgical/ 
 Blood Vessel Prosthesis/ 
 Blood Vessel Prosthesis Implantation/ 
 (vascular access or venous access).tw. 
 (dialysis access or hemodialysis access or haemodialysis access).tw. 
 Catheterization, Central Venous/ 
 fistula$.tw. 
 (graft or grafts).tw. 
 (shunt or shunts).tw. 
 prosthesis.tw. 
 tunne$.tw. 
 catheter$.tw. 
 central line$.tw. 
 (AVF or AVG or CVC).tw. 
 Kidney Failure/ 
 exp Renal Insufficiency, Chronic/ 
 (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw. 
 (ESRF or ESKF or ESRD or ESKD).tw. 
 (chronic kidney or chronic renal).tw. 
 (CKF or CKD or CRF or CRD).tw. 
 predialysis.tw. 
 *Kidney Transplantation/ or exp *Peritoneal Dialysis/ 
 exp diabetes mellitus/ 
 Diabetes Mellitus, Type 1/ 
 Diabetes Mellitus, Type 2/ 
 Diabetic Nephropathies/ 
 diabet$.tw. 
 (niddm or iddm).tw. 
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